Paloma Martin

Madrid, MD, ES 
Madrid, MD, ES 

Overview

Paloma Martin practices practicing medicine in Madrid, Spain.

Her clinical expertise encompasses Classical Hodgkin Lymphoma, Mononucleosis, Lung Cancer, and Cerebral Ventricle Cancer.

She is actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 7 clinical trials.

Gender

Female

Locations

Madrid, MD 28049, Spain
Other Locations
Valencia, VC, Spain
Majadahonda, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Clinical Trial of Adjuvant Chemotherapy vs Chemoimmunotherapy for Stage IB-IIIA Completely Resected Non-small Cell Lung Cancer (NSCLC) Patients.
A Phase III Clinical Trial of Adjuvant Chemotherapy vs Chemoimmunotherapy for Stage IB-IIIA Completely Resected Non-small Cell Lung Cancer (NSCLC) Patients.
Enrollment Status: Active_not_recruiting
Publish Date: May 05, 2026
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Nivolumab
Study Phase: Phase 3
A Phase II Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Phase II Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Single Arm Clinical Trial Assessing the Efficacy and Safety of BIntrafusp Alfa (M7824) in Previously Treated Advanced Malignant Pleural MESothelioma (BIMES)
A Phase II Single Arm Clinical Trial Assessing the Efficacy and Safety of BIntrafusp Alfa (M7824) in Previously Treated Advanced Malignant Pleural MESothelioma (BIMES)
Enrollment Status: Completed
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drug: Bintrafusp alfa
Study Phase: Phase 2
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Atezolizumab+Bevacizumab
Study Phase: Phase 2
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Retrospective, Observational Study On The Efficacy And Safety Of Lorlatinib In ALK or ROS1 Metastatic Non-Small Cell Lung Cancer Patients Treated Within The Compassionate Use Program In Spain
Retrospective, Observational Study On The Efficacy And Safety Of Lorlatinib In ALK or ROS1 Metastatic Non-Small Cell Lung Cancer Patients Treated Within The Compassionate Use Program In Spain
Enrollment Status: Completed
Publish Date: March 30, 2023
Intervention Type: Drug
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Enrollment Status: Completed
Publish Date: June 27, 2022
View 6 Less Clinical Trials

34 Total Publications

Drosophila male genitalia rotation depends on permissive remodeling of the posterior abdomen.
Drosophila male genitalia rotation depends on permissive remodeling of the posterior abdomen.
Journal: Developmental dynamics : an official publication of the American Association of Anatomists
Published: March 29, 2026

Frequently Asked Questions about Paloma Martin

Is Paloma Martin a top-rated expert for Classical Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Paloma Martin is classified as an Experienced expert for Classical Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Paloma Martin participate in research or clinical trials?

Yes. Paloma Martin has published 34 articles and abstracts on conditions like Classical Hodgkin Lymphoma. You can view a list of Paloma Martin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Martin's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile